Financial Report Insights

argenx SE(ARGX) earnings

United States · NASDAQ

Latest results · H1 (Interim) 2026Revenue $2.9B (+60.8%) · EPS $13.00 (+105.7%)argenx now earns a 31% operating margin on a single drug franchise while still increasing R&D by 45% a year. That is because SG&A grows at less than half the rate of sales. Its $5.2 billion in cash and its profits pay for the late-stage pipeline, so the company's value depends mainly on whether those trials succeed, not on raising money. The weak points are concentration: about 85% of sales come from the US and about 72% go through three US customers, so any pricing or reimbursement pressure in the US would hit the whole business.Read the full analysis →

Next earnings reportOct 22, 20266-K (Q3 2026 results) · Confirmed dateEarnings calendar

argenx SE results by period

Period	Revenue	Rev. YoY	Net income	Diluted EPS	Op. margin
H1 (Interim) 2026	$2.9B	+60.8%	$838M	$13.00	31.1%

Figures as reported in each period's filing; YoY compares with the same period a year earlier. Money in the reporting currency.

Write your own report

argenx SE earnings analyses

argenx SE (ARGX) · H1 (Interim) 2026
Revenue $2.9B (+60.8%) · EPS $13.00 (+105.7%)
argenx H1 2026: VYVGART product net sales rose 62% to $2.81B (Q2 $1.52B, +60%), lifting operating margin to 31.1% and diluted EPS to $13.00 from $6.32.